Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective cohort study of immunogenicity and reactogenicity US Food and Drug Administration Emergency Use Authorization vaccines in a large cohort of patients: Cancer, COVID, and Vaccination (CANVAX) study

X
Trial Profile

A prospective cohort study of immunogenicity and reactogenicity US Food and Drug Administration Emergency Use Authorization vaccines in a large cohort of patients: Cancer, COVID, and Vaccination (CANVAX) study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ad26.COV2 S (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
  • Indications Cancer
  • Focus Pharmacodynamics
  • Acronyms CANVAX
  • Most Recent Events

    • 09 Dec 2021 Results from this and other studies comparing the immunogenicity of mRNA-1273, BNT-162b2 or Ad26.COV2.S in healthy ambulatory adults, published in the Journal of Infectious Diseases
    • 15 Nov 2021 New trial record
    • 09 Nov 2021 Primary endpoint (neutralization titers) has been met, according to Results published in the Journal of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top